Search

EP-3870566-B1 - PD-1/PD-L1 INHIBITORS

EP3870566B1EP 3870566 B1EP3870566 B1EP 3870566B1EP-3870566-B1

Inventors

  • DU, ZHIMIN
  • ZIEBENHAUS, Christopher A.
  • PHILLIPS, BARTON
  • GRAUPE, MICHAEL
  • MACHICAO TELLO, Paulo A.
  • MEDLEY, Jonathan William
  • METOBO, SAMUEL E.
  • PARKHILL, Eric Q.
  • SIMONOVICH, Scott P.
  • WANG, PEIYUAN
  • XU, JIE

Dates

Publication Date
20260506
Application Date
20191022

Claims (20)

  1. A compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X 1 is N, CH, or CZ 3 ; X 2 is N, CH, or CZ 3 ; Y 1 is O, NH, or CH 2 and the dashed lines (- - -) are single bonds, or Y 1 is halo or -C 1 - 6 alkyl and the dashed lines (- - -) are absent; ring B is a 9-, 10-, or 11-membered fused bicyclic heterocyclyl or heteroaryl ring of the formula: wherein X 3 , X 4 , X 5 , and X 6 are each independently N or CH; X 7 and X 8 are each independently S, N, NH, CH or CH 2 ; X 9 , X 10 , X 11 , and X 12 are each independently O, S, NH or CH 2 ; X 13 is N or C; ring C is cycloalkyl, heterocyclyl, aryl, or heteroaryl; and ring D is heteroaryl; w is 0, 1, or 2; each Z 1 is independently halo, -OR a , -NO 2 , cyano, -NR a R b , -N 3 , -S(O) 2 R a , -C 1 - 6 alkyl, -C 1 - 6 haloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -O-C 1 - 6 alkyl, -O-C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, or -C 1 - 6 alkylC 3 - 8 cycloalkyl; and wherein each alkyl, alkenyl, alkynyl, and cycloalkyl is optionally substituted with 1 to 4 groups independently selected from oxo, -NO 2 , -N 3 , -OR a , halo, and cyano; x is 0, 1, or 2; each Z 2 is independently halo, -OR a , -NO 2 , cyano, -NR a R b , -N 3 , -S(O) 2 R a , -C 1 - 6 alkyl, -C 1 - 6 haloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -O-C 1 - 6 alkyl, -O-C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, or -C 1 - 6 alkylC 3 - 8 cycloalkyl; and wherein each alkyl, alkenyl, alkynyl, and cycloalkyl is optionally substituted with 1 to 4 groups independently selected from oxo, -NO 2 , -N 3 , -OR a , halo, and cyano; t is 0, 1, or 2; each Z 3 is independently halo, -OR a , -N 3 , -NO 2 , cyano, -NR 1 R 2 , -S(O) 2 R a , -S(O) 2 NR a R b , -NR a S(O) 2 R a , -NR a C(O)R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -NR a C(O)OR a , -NR a C(O)NR 1 R 2 , -OC(O)NR a R b , -NR a S(O) z NR a R b , -C(O)NR a S(O) 2 NR a R b , -C 1 - 6 alkyl. -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -O-C 1 - 6 alkyl, -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, -O-C 1 - 6 cyanoalkyl, -O-C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, -C 1 - 6 alkylC 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, or R N ; and wherein the alkyl, alkenyl, alkynyl, C 3 - 8 cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from oxo, -NO 2 , -N 3 , -OR a , halo, cyano, -NR a R b , -C(O)R a , -C(O)OR a , -O-C 1-6 cyanoalkyl, -C(O)NR a R b , -NR a C(O)R a , -NR a C(O)OR a , -S(O) 2 R a , -NR a S(O) 2 R b , -S(O) 2 NR a R b , -NR a S(O) 2 NR a R b , -C(O)NR a S(O) 2 NR a R b , and -C 3 - 8 cycloalkyl; R N is independently -C 1 - 6 alkylNR 1 R 2 , -OC 1 - 6 alkylNR 1 R 2 , -C 1 - 6 alkyl-O-C 1 - 6 alkylNR 1 R 2 , -NR a C 1 - 6 alkylNR 1 R 2 , -C 1 - 6 alkylC(O)NR 1 R 2 , -O-C 1 - 6 alkylC(O)NR 1 R 2 , -O-C 1 - 6 alkylC(O)OR 1 , -SC 1 - 6 alkylNR 1 R 2 , -C 1 - 6 alkylOR a , or wherein: L 1 is independently a bond, -O-, -NR a -, -S-, -S(O)-, or -S(O) 2 -; V is independently selected from a bond, C 1 - 6 alkyl, C 2 - 6 alkenyl, and C 2 - 6 alkynyl; wherein each alkyl, alkenyl, or alkynyl is optionally independently substituted with -OR a , halo, cyano, -NR a R b , or -C 3 - 8 cycloalkyl; L 2 is independently a bond, -O-, -NR a -, -S-, -S(O)-, or -S(O) 2 -; ring A is independently cycloalkyl, aryl, heteroaryl, or heterocyclyl; wherein each cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 4 groups independently selected from oxo, -NO 2 , -N 3 , -OR a , halo, cyano, -C 1 - 6 alkyl, -C 1 - 6 haloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -O-C 1 - 6 haloalkyl, -NR a R b , -C(O)R a , -C(O)OR a , -O-C 1 - 6 cyanoalkyl, -C(O)NR a R b , -NR a C(O)R a , -NR a C(O)OR a , -C(O)N(R a )OR b , -S(O) 2 R a , -S(O) 2 NR a R b , -NR a S(O) 2 R b , -NR a S(O) 2 NR a R b , -C(O)NR a S(O) 2 NR a R b , -C 3 - 8 cycloalkyl, and -C 1 - 6 alkylC 3 - 8 cycloalkyl; and wherein the alkyl, alkenyl, or alkynyl group is optionally independently substituted with -OR a , halo, cyano, -NR a R b , or -C 3 - 8 cycloalkyl; R E is hydrogen, -OH, -NR 1 C(O)NR 1 R 2 , -C 1 - 6 alkylOC(O)NR 1 R 2 , or -C 1-6 alkylNR 1 C(O)R 2 ; R W is -NR 1 R 2 , -C 1-6 alkylNR 1 R 2 , -O-C 1-6 alkylNR 1 R 2 , -C 1 - 6 alkyl-O-C 1 - 6 alkylNR 1 R 2 , -NR a -C 1 - 6 alkylNR 1 R 2 , -C 1 - 6 alkylN + R 1 R 2 R 3 , -S-C 1 - 6 alkylNR 1 R 2 , -C(O)NR 1 R 2 , -S(O) 2 R a , -(CH 2 ) u S(O) 2 NR 1 R 2 , -(CH 2 ) u NR a S(O) 2 NR a R b , -S(O) 2 NR a C 1-6 alkylNR 1 R 2 , -NR a S(O) 2 C 1-6 alkylNR 1 R 2 , -(CH 2 ) u C(O)NR a S(O) 2 NR a R b , -(CH 2 ) u N + R 1 R 2 O - , -(CH 2 ) u P + R b R c R d , -(CH 2 ) u P + R c R d O - , -(CH 2 ) u P + O[NR a R b ][NR c R d ], -(CH 2 ) u NR c P(O)(OR c ) 2 , -(CH 2 ) u CH 2 OP(O)(OR c )(OR d ), -(CH 2 ) u OP(O)(OR c )(OR d ), -(CH 2 ) u OP(O)NR a R b )(OR a ), or wherein: V 2 is independently a bond, -O-, -NR a -, -S-, -S(O)-, -S(O) 2 -, -C(O)NR a -, -NR a C(O)-, -S(O) 2 NR 1 -, or -NR a S(O) 2 -; L 3 is independently a bond, -O-, -NR a -, -S-, -S(O)-, -S(O) 2 -, -C(O)NR a -, -NR a C(O)-, -S(O) 2 NR 1 -, or -NR a S(O) 2 -; ring B is independently cycloalkyl, aryl, heteroaryl, or heterocyclyl; T is independently hydrogen, -OR a , -(CH 2 ) q NR 1 R 2 , -(CH 2 ) q NR a C(O)R e , or -(CH 2 ) q C(O)R e ; p is independently 0, 1, 2, 3, 4, or 5; q is independently 0, 1, 2, 3, 4, or 5; u is 0, 1, 2, 3, or 4; z is 0, 1, 2, or 3; and wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R E or R W is optionally substituted with 1 to 3 substituents independently selected from the group consisting of -NR a R b , halo, cyano, oxo, -OR a , -C 1 - 6 alkyl, -C 1 - 6 haloalkyl, -C 1 - 6 cyanoalkyl, -C 1 - 6 alkylNR a R b , -C 1 - 6 hydroxyalkyl, -C 3 - 8 cycloalkyl, and -C 1 - 3 alkylC 3 - 8 cycloalkyl; provided that at least one of V 2 , L 3 , ring B, and T contains a nitrogen atom; each R 1 is independently selected from hydrogen, -C 1 - 8 alkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -C 3 - 6 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, -C 1 - 6 alkylheterocyclyl, -C 1 - 6 alkylC(O)OR a , -C 2 - 6 alkenylC(O)OR a , -S(O) 2 R a , -S(O) 2 NR a R b , -C(O)NR a S(O) 2 R a , and -C 1 - 6 alkylC 3 - 8 cycloalkyl; wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 4 groups independently selected from -OR a , cyano, halo, C 1 - 6 alkyl, -C 1 - 6 alkylOR a , -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, C 3 - 8 cycloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R a , -C 1 - 6 alkylC(O)R a , -C(O)OR a , -C 1 - 6 alkylC(O)OR a , -NR a R b , -OC(O)NR a R b , NR a C(O)OR b , -C 1 - 6 alkylNR a R b , -C(O)NR a R b , -C 1 - 6 alkylC(O)NR a R b , -S(O) 2 R a , -C 1 - 6 alkylS(O) 2 R a , -S(O) 2 NR a R b , -C 1 - 6 alkylS(O) 2 NR a R b , -C(O)NR a S(O) 2 R b , -C 1 - 6 alkylC(O)NR a S(O) 2 R b , -NR a C(O)R b , and -C 1 - 6 alkylNR a C(O)R b ; each R 2 is independently selected from hydrogen, -C 1 - 6 alkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -C 3 - 6 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, -C 1 - 6 alkylheterocyclyl, -C 2 - 6 alkyl-OR a , -C 1 - 6 alkylC(O)OR a , and -C 2 - 6 alkenylC(O)OR a ; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 4 groups independently selected from -OR a , cyano, halo, C 1 - 6 alkyl, -C 1 - 6 alkylOR a , -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R a , -C 1 - 6 alkylC(O)R a , -C(O)OR a , -C 1 - 6 alkylC(O)OR a , -NR a R b , -C 1 - 6 alkylNR a R b , -C(O)NR a R b , C 1 - 6 alkylC(O)NR a R b , -S(O) 2 R a , -C 1 - 6 alkylS(O) 2 R a , -S(O) 2 NR a R b , -C 1 - 6 alkylS(O) 2 NR a R b , -C(O)NR a S(O) 2 R b , and -NR a C(O)R b ; or R 1 and R 2 combine to form a heterocyclyl optionally substituted with 1 to 3 groups independently selected from oxo, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -OR a , -C(O)OR a , -C 1 - 6 cyanoalkyl, -C 1 - 6 alkylOR a , -C 1 - 6 haloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R a , -C 1 - 6 alkylC(O)R a , -C 1 - 6 alkylC(O)OR a , -NR a R b , -C 1 - 6 alkylNR a R b , -C(O)NR a R b , -C 1 - 6 alkylC(O)NR a R b , -S(O) 2 R a , -C 1 - 6 alkylS(O) 2 R a , -S(O) 2 NR a R b , -C(O)N=S(O)R a NR a R b , -C(O)N=S(O)R a NR a C(O)R b , and -C 1 - 6 alkylS(O) 2 NR a R b ; each R 3 is independently hydrogen, -C 1 - 6 alkyl, -C 2 - 6 alkenyl, -C 3 - 6 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, -C 1 - 6 alkylheterocyclyl, -C 2 - 6 alkyl-OR a , -C 1 - 6 alkylC(O)OR a , or -C 2 - 6 alkenylC(O)OR a ; each R a is independently selected from hydrogen, -C 1 - 6 alkyl, -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl , -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; each R b is independently selected from hydrogen, -C 1 - 6 alkyl, -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; or R a and R b may combine together to form a heterocyclyl optionally substituted with 1 to 4 groups independently selected from -OR f , cyano, halo, -C 1 - 6 alkylOR f , -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R f , -C 1 - 6 alkylC(O)R f , -C(O)OR f , -C 1 - 6 alkylC(O)OR f , -NR f R g , -C 1 - 6 alkylNR f R g , -C(O)NR f R g , -C 1 - 6 alkylC(O)NR f R g , -S(O) 2 R f , -C 1 - 6 alkylS(O) 2 R f , -S(O) 2 NR f R g , -C 1 - 6 alkylS(O) 2 NR f R g , -C(O)NR f S(O) 2 R g , and -NR f C(O)R g ; each R c is independently selected from hydrogen, -OH, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; each R d is independently selected from hydrogen, -C 1 - 6 alkyl, -C 3 -C 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; each R e is independently selected from hydrogen, -C 1 - 6 alkyl, -O-C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -O-C 3 - 8 cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, -NR f R g , -C 1 - 6 alkylNR f R g , -C(O)NR f R g , -C 1 - 6 alkylC(O)NR f R g , -NHS(O) 2 R f , -C 1 - 6 alkylS() 2 R f , and -C 1 - 6 alkylS(O) 2 NR f R g ; each R f is independently selected from hydrogen, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; and each R g is independently selected from hydrogen, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl.
  2. A compound of Formula (II): or a pharmaceutically acceptable salt thereof, wherein: X 1 is N, CH, or CZ 3 ; X 2 is N, CH, or CZ 3 ; Y 1 is halo or -C 1 - 6 alkyl; ring B is a 9-, 10-, or 11-membered fused bicyclic heterocyclyl or heteroaryl ring of the formula: wherein X 3 , X 4 , X 5 , and X 6 are each independently N or CH; X 7 and X 8 are each independently S, N, NH, CH or CH 2 ; X 9 , X 10 , X 11 ,and X 12 are each independently O, S, NH or CH 2 ; X 13 is N or C; ring C is cycloalkyl, heterocyclyl, aryl, or heteroaryl; and ring D is heteroaryl; w is 0, 1, or 2; each Z 1 is independently halo, -OR a , -NO 2 , cyano, -NR a R b , -N 3 , -S(O) 2 R a , -C 1 - 6 alkyl, -C 1 - 6 haloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -O-C 1 - 6 alkyl, -O-C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, or -C 1 - 6 alkylC 3 - 8 cycloalkyl; and wherein each alkyl, alkenyl, alkynyl, and cycloalkyl is optionally substituted with 1 to 4 groups independently selected from oxo, -NO 2 , -N 3 , -OR a , halo, and cyano; x is 0, 1, or 2; each Z 2 is independently halo, -OR a , -NO 2 , cyano, -NR a R b , -N 3 , -S(O) 2 R a , -C 1 - 6 alkyl, -C 1 - 6 haloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -O-C 1 - 6 alkyl, -O-C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, or -C 1 - 6 alkylC 3 - 8 cycloalkyl; and wherein each alkyl, alkenyl, alkynyl, and cycloalkyl is optionally substituted with 1 to 4 groups independently selected from oxo, -NO 2 , -N 3 , -OR a , halo, and cyano; t is 0, 1, or 2; each Z 3 is independently halo, -OR a , -N 3 , -NO 2 , cyano, -NR 1 R 2 , -S(O) 2 R a , -S(O) 2 NR a R b , -NR a S(O) 2 R a , -NR a C(O)R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -NR a C(O)OR a , -NR a C(O)NR 1 R 2 , -OC(O)NR a R b , -NR a S(O) 2 NR a R b , -C(O)NR a S(O) 2 NR a R b , -C 1 - 6 alkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -O-C 1 - 6 alkyl, -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, -O-C 1 - 6 cyanoalkyl, -O-C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, -C 1 - 6 alkylC 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, or R N ; and wherein the alkyl, alkenyl, alkynyl, C 3 - 8 cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from oxo, -NO 2 , -N 3 , -OR a , halo, cyano, -NR a R b , -C(O)R a , -C(O)OR a , -O-C 1-6 cyanoalkyl, -C(O)NR a R b , -NR a C(O)R a , -NR a C(O)OR a , -S(O) 2 R a , -NR a S(O) 2 R b , -S(O) 2 NR a R b , -NR a S(O) 2 NR a R b , -C(O)NR a S(O) 2 NR a R b , and -C 3 - 8 cycloalkyl; R N is independently -C 1 - 6 alkylNR 1 R 2 , -OC 1 - 6 alkylNR 1 R 2 , -C 1 - 6 alkyl-O-C 1 - 6 alkylNR 1 R 2 , -NR a C 1 - 6 alkylNR 1 R 2 , -C 1 - 6 alkylC(O)NR 1 R 2 , -O-C 1 - 6 alkylC(O)NR 1 R 2 , -O-C 1 - 6 alkylC(O)OR 1 , -SC 1 - 6 alkylNR 1 R 2 , -C 1 - 6 alkylOR a , or wherein: L 1 is independently a bond, -O-, -NR a -, -S-, -S(O)-, or -S(O) 2 -; V is independently selected from a bond, C 1 - 6 alkyl, C 2 - 6 alkenyl, and C 2 - 6 alkynyl; wherein each alkyl, alkenyl, or alkynyl is optionally independently substituted with -OR a , halo, cyano, -NR a R b , or -C 3 - 8 cycloalkyl; L 2 is independently a bond, -O-, -NR a -, -S-, -S(O)-, or -S(O) 2 -; ring A is independently cycloalkyl, aryl, heteroaryl, or heterocyclyl; wherein each cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 4 groups independently selected from oxo, -NO 2 , -N 3 , -OR a , halo, cyano, -C 1 - 6 alkyl, -C 1 - 6 haloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -O-C 1 - 6 haloalkyl, -NR a R b , -C(O)R a , -C(O)OR a , -O-C 1 - 6 cyanoalkyl, -C(O)NR a R b , -NR a C(O)R a , -NR a C(O)OR a , -C(O)N(R a )OR b , -S(O) 2 R a , -S(O) 2 NR a R b , -NR a S(O) 2 R b , -NR a S(O) 2 NR a R b , -C(O)NR a S(O) 2 NR a R b , -C 3 - 8 cycloalkyl, and -C 1 - 6 alkylC 3 - 8 cycloalkyl; and wherein the alkyl, alkenyl, or alkynyl group is optionally independently substituted with -OR a , halo, cyano, -NR a R b , or -C 3 - 8 cycloalkyl; R E is hydrogen, -OH, -NR 1 C(O)NR 1 R 2 , -C 1 - 6 alkylOC(O)NR 1 R 2 , or -C 1 - 6 alkylNR 1 C(O)R 2 ; R W is -NR 1 R 2 , -C 1-6 alkylNR 1 R 2 , -O-C 1 - 6 alkylNR 1 R 2 , -C 1 - 6 alkyl-O-C 1 - 6 alkylNR 1 R 2 , -NR a -C 1 - 6 alkylNR 1 R 2 , -C 1 - 6 alkylN + R 1 R 2 R 3 , -S-C 1 - 6 alkylNR 1 R 2 , -C(O)NR 1 R 2 , -S(O) 2 R a , -(CH 2 ) u S(O) 2 NR 1 R 2 , -(CH 2 ) u NR a S(O) 2 NR a R b , -S(O) 2 NR a C 1 - 6 alkylNR 1 R 2 , -NR a S(O) 2 C 1 - 6 alkylNR 1 R 2 , -(CH 2 ) u C(O)NR a S(O) 2 NR a R b , -(CH 2 ) u N + R 1 R 2 O - , -(CH 2 ) u P + R b R c R d , -(CH 2 ) u P + R c R d O - , -(CH 2 ) u P + O[NR a R b ][NR c R d ], -(CH 2 ) u NR c P(O)(OR c ) 2 , -(CH 2 ) u CH 2 OP(O)(OR c )(OR d ), -(CH 2 ) u OP(O)(OR c )(OR d ), -(CH 2 ) u OP(O)NR a R b )(OR a ), or wherein: V 2 is independently a bond, -O-, -NR a -, -S-, -S(O)-, -S(O) 2 -, -C(O)NR a -, -NR a C(O)-, -S(O) 2 NR 1 -, or -NR a S(O) 2 -; L 3 is independently a bond, -O-, -NR a -, -S-, -S(O)-, -S(O) 2 -, -C(O)NR a -, -NR a C(O)-, -S(O) 2 NR 1 -, or -NR a S(O) 2 -; ring B is independently cycloalkyl, aryl, heteroaryl, or heterocyclyl; T is independently hydrogen, -OR a , -(CH 2 ) q NR 1 R 2 , -(CH 2 ) q NR a C(O)R e , or -(CH 2 ) q C(O)R e ; p is independently 0, 1, 2, 3, 4, or 5; q is independently 0, 1, 2, 3, 4, or 5; u is 0, 1, 2, 3, or 4; z is 0, 1, 2, or 3; and wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R E or R W is optionally substituted with 1 to 3 substituents independently selected from the group consisting of -NR a R b , halo, cyano, oxo, -OR a , -C 1 - 6 alkyl, -C 1 - 6 haloalkyl, -C 1 - 6 cyanoalkyl, -C 1 - 6 alkylNR a R b , -C 1 - 6 hydroxyalkyl, -C 3 - 8 cycloalkyl, and -C 1 - 3 alkylC 3 - 8 cycloalkyl; provided that at least one of V 2 , L 3 , ring B, and T contains a nitrogen atom; each R 1 is independently selected from hydrogen, -C 1 - 8 alkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -C 3 - 6 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, -C 1 - 6 alkylheterocyclyl, -C 1 - 6 alkylC(O)OR a , -C 2 - 6 alkenylC(O)OR a , -S(O) 2 R a , -S(O) 2 NR a R b , -C(O)NR a S(O) 2 R a , and -C 1 - 6 alkylC 3 - 8 cycloalkyl; wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 4 groups independently selected from -OR a , cyano, halo, C 1 - 6 alkyl, -C 1 - 6 alkylOR a , -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, C 3 - 8 cycloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R a , -C 1 - 6 alkylC(O)R a , -C(O)OR a , -C 1 - 6 alkylC(O)OR a , -NR a R b , -OC(O)NR a R b , NR a C(O)OR b , -C 1 - 6 alkylNR a R b , -C(O)NR a R b , -C 1 - 6 alkylC(O)NR a R b , -S(O) 2 R a , -C 1 - 6 alkylS(O) 2 R a , -S(O) 2 NR a R b , -C 1 - 6 alkylS(O) 2 NR a R b , -C(O)NR a S(O) 2 R b , -C 1 - 6 alkylC(O)NR a S(O) 2 R b , -NR a C(O)R b , and -C 1 - 6 alkylNR a C(O)R b ; each R 2 is independently selected from hydrogen, -C 1 - 6 alkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -C 3 - 6 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, -C 1 - 6 alkylheterocyclyl, -C 2 - 6 alkyl-OR a , -C 1 - 6 alkylC(O)OR a , and -C 2 - 6 alkenylC(O)OR a ; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 4 groups independently selected from -OR a , cyano, halo, -C 1 - 6 alkyl, -C 1 - 6 alkylOR a , -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R a , -C 1 - 6 alkylC(O)R a , -C(O)OR a , -C 1 - 6 alkylC(O)OR a , -NR a R b , -C 1 - 6 alkylNR a R b , -C(O)NR a R b , C 1 - 6 alkylC(O)NR a R b , -S(O) 2 R a , -C 1 - 6 alkylS(O) 2 R a , -S(O) 2 NR a R b , -C 1 - 6 alkylS(O) 2 NR a R b , -C(O)NR a S(O) 2 R b , and -NR a C(O)R b ; or R 1 and R 2 combine to form a heterocyclyl optionally substituted with 1 to 3 groups independently selected from oxo, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -OR a , -C(O)OR a , -C 1 - 6 cyanoalkyl, -C 1 - 6 alkylOR a , -C 1 - 6 haloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R a , -C 1 - 6 alkylC(O)R a , -C 1 - 6 alkylC(O)OR a , -NR a R b , -C 1 - 6 alkylNR a R b , -C(O)NR a R b , -C 1 - 6 alkylC(O)NR a R b , -S(O) 2 R a , -C 1 - 6 alkylS(O) 2 R a , -S(O) 2 NR a R b , -C(O)N=S(O)R a NR a R b , -C(O)N=S(O)R a NR a C(O)R b , and -C 1 - 6 alkylS(O) 2 NR a R b ; each R 3 is independently hydrogen, -C 1 - 6 alkyl, -C 2 - 6 alkenyl, -C 3 - 6 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, -C 1 - 6 alkylheterocyclyl, -C 2 - 6 alkyl-OR a , -C 1 - 6 alkylC(O)OR a , or -C 2 - 6 alkenylC(O)OR a ; each R a is independently selected from hydrogen, -C 1 - 6 alkyl, -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; each R b is independently selected from hydrogen, -C 1 - 6 alkyl, -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; or R a and R b may combine together to form a heterocyclyl optionally substituted with 1 to 4 groups independently selected from -OR f , cyano, halo, -C 1 - 6 alkylOR f , -C 1 - 6 cyanoalkyl, -C 1 - 6 haloalkyl, -C 3 - 8 cycloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R f , -C 1 - 6 alkylC(O)R f , -C(O)OR f , -C 1 - 6 alkylC(O)OR f , -NR f R g , -C 1 - 6 alkylNR f R g , -C(O)NR f R g , -C 1 - 6 alkylC(O)NR f R g , -S(O) 2 R f , -C 1 - 6 alkylS(O) 2 R f , -S(O) 2 NR f R g , -C 1 - 6 alkylS(O) 2 NR f R g , -C(O)NR f S(O) 2 R g , and -NR f C(O)R g ; each R c is independently selected from hydrogen, -OH, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; each R d is independently selected from hydrogen, -C 1 - 6 alkyl, -C 3 -C 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; each R e is independently selected from hydrogen, -C 1 - 6 alkyl, -O-C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -O-C 3 - 8 cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, -NR f R g , -C 1 - 6 alkylNR f R g , -C(O)NR f R g , -C 1 - 6 alkylC(O)NR f R g , -NHS(O) 2 R f , -C 1 - 6 alkylS() 2 R f , and -C 1 - 6 alkylS(O) 2 NR f R g ; each R f is independently selected from hydrogen, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl; and each R g is independently selected from hydrogen, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C 1 - 6 alkylaryl, -C 1 - 6 alkylheteroaryl, and -C 1 - 6 alkylheterocyclyl.
  3. The compound of claim 1 or 2, wherein Z 1 and Z 2 are each independently halo, -NH 2 , -OH, cyano, -C 1 - 6 alkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -C 1 - 6 haloalkyl, or -O-C 1-6 alkyl.
  4. The compound of claim 1 or 2, wherein Z 1 and Z 2 are each independently halo, or -C 1 - 6 alkyl.
  5. The compound of any preceding claim, wherein t is 1.
  6. The compound of any preceding claim, wherein X 7 is N or S and X 8 is N or CH.
  7. The compound of any preceding claim, wherein X 7 is S and X 8 is N.
  8. The compound of any preceding claim, wherein X 7 is S and X 8 is CH.
  9. The compound of any preceding claim, wherein X 7 is N and X 8 is N.
  10. The compound of any preceding claim, wherein each Z 1 is independently halo.
  11. The compound of any preceding claim, wherein Z 3 is halo, -C 1 - 6 alkyl, C 1 - 6 haloalkyl, -O-C 1 - 6 cyanoalkyl, -O-C 1 - 6 haloalkyl, or -O-C 1 - 6 alkyl.
  12. The compound of any preceding claim, wherein Z 3 is of the formula: V is independently selected from a bond, C 1 - 6 alkyl, C 2 - 6 alkenyl, and C 2 - 6 alkynyl; wherein each alkyl, alkenyl, or alkynyl is optionally independently substituted with -OR a , halo, cyano, -NR a R b , or -C 3 - 8 cycloalkyl; ring A is independently cycloalkyl, aryl, heteroaryl, or heterocyclyl; wherein each cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 4 groups independently selected from oxo, -NO 2 , -N 3 , -OR a , halo, cyano, -C 1 - 6 alkyl, -C 1 - 6 haloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -O-C 1 - 6 haloalkyl, NR a R b , -C(O)R a , -C(O)OR a , -OC 1 - 6 alkylCN, -C(O)NR a R b , -NR a C(O)R a , -NR a C(O)OR a , -C(O)N(R a )OR b , -S(O) 2 R a , -S(O) 2 NR a R b , -NR a S(O) 2 R b , -NR a S(O) 2 NR a R b , -C(O)NR a S(O) 2 NR a R b , -C 3 - 8 cycloalkyl, and -C 1 - 6 alkylC 3 - 8 cycloalkyl.
  13. The compound of any preceding claim, wherein R W is -C 1 - 6 alkylNR 1 R 2 , where R 1 and R 2 combine to form a heterocyclyl optionally substituted with 1 to 3 groups independently selected from oxo, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -OR a , -C(O)OR a , -C 1 - 6 cyanoalkyl, -C 1 - 6 alkylOR a , -C 1 - 6 haloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R a , -C 1 - 6 alkylC(O)R a , -C 1 - 6 alkylC(O)OR a , -NR a R b , -C 1 - 6 alkylNR a R b , -C(O)NR a R b , -C 1 - 6 alkylC(O)NR a R b , -S(O) 2 R a , -C 1 - 6 alkylS(O) 2 R a , -S(O) 2 NR a R b , -C(O)N=S(O)R a NR a R b , -C(O)N=S(O)R a NR a C(O)R b , and -C 1 - 6 alkylS(O) 2 NR a R b ; or -C 1 - 6 alkylNR 1 R 2 , where R 1 is hydrogen and R 2 is -C 1 - 6 alkylheteroaryl or -C 1 - 6 alkylheterocyclyl.
  14. The compound of any preceding claim, wherein R E is hydrogen and R W is -C 1 - 6 alkylNR 1 R 2 .
  15. The compound of claim 14, wherein R 1 and R 2 combine to form a heterocyclyl optionally substituted with 1 to 3 groups independently selected from oxo, -C 1 - 6 alkyl, -C 3 - 8 cycloalkyl, -C 2 - 6 alkenyl, -C 2 - 6 alkynyl, -OR a , -C(O)OR a , -C 1 - 6 cyanoalkyl, -C 1 - 6 alkylOR a , -C 1 - 6 haloalkyl, -C 1 - 3 alkylC 3 - 8 cycloalkyl, -C(O)R a , -C 1 - 6 alkylC(O)R a , -C 1 - 6 alkylC(O)OR a , -NR a R b , -C 1 - 6 alkylNR a R b , -C(O)NR a R b , -C 1 - 6 alkylC(O)NR a R b , -S(O) 2 R a , -C 1 - 6 alkylS(O) 2 R a , -S(O) 2 NR a R b , -C(O)N=S(O)R a NR a R b , - C(O)N=S(O)R a NR a C(O)R b , and -C 1 - 6 alkylS(O) 2 NR a R b .
  16. The compound of any preceding claim, wherein R 1 is hydrogen and R 2 is -C 1 - 6 alkylheteroaryl or -C 1 - 6 alkylheterocyclyl.
  17. A compound, or a pharmaceutically acceptable salt thereof, selected from: No Structure 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
  18. A pharmaceutical composition comprising a compound according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  19. The pharmaceutical composition according to claim 18, further comprising at least one additional anticancer agent or therapy selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, and ipilimumab, and at least one pharmaceutically acceptable excipient.
  20. A compound according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, for use in treating cancer.

Description

FIELD The present disclosure generally relates to compounds useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Provided herein are compounds, compositions comprising such compounds, and methods for their use. BACKGROUND Programmed death-1 (CD279) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1, CD274, B7-H1) or PD-L2 (CD273, B7-DC). When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self-tolerance. Chronic antigen stimulation, such as that which occurs during tumor disease or chronic infections, results in T cells that express elevated levels of PD-1 and are dysfunctional with respect to activity towards the chronic antigen. This is termed "T cell exhaustion." B cells also display PD-l/PD-ligand suppression and "exhaustion." Blockade of the PD-1/PD-L1 ligation using antibodies to PD-L1 has been shown to restore and augment T cell activation in many systems. Patients with advanced cancer benefit from therapy with a monoclonal antibody to PD-L1. Preclinical animal models of tumors and chronic infections have shown that blockade of the PD-1/PD-L1 pathway by monoclonal antibodies can enhance the immune response and result in tumor rejection or control of infection. Antitumor immunotherapy via PD-1/PD-L1 blockade may augment therapeutic immune response to a number of histologically distinct tumors. Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1. Humanized mice infected with HIV-1 show enhanced protection against viremia and viral depletion of CD4+ T cells. Blockade of PD-1/PD-L1 through monoclonal antibodies to PD-L1 can restore in vitro antigen-specific functionality to T cells from HIV patients, HCV patients or HBV patients. Accordingly, agents that block PD-1, PD-L1 and/or the PD-1/PD-L1 interaction are desired. Small molecule agents that block or inhibit PD-1, PD-L1 and/or the PD-1/PD-L1 interaction are particularly desired. US 2018/008554 A1 and WO 2015/034820 A1 disclose indanyloxyphenyl and benzyloxyphenyl derivatives as PD-1/PD-L1 inhibitors. Applicants have discovered small molecule compounds that have activity as inhibitors of PD-1, PD-L1 or inhibitors of the interaction of PD-1 with PD-L1, and thus may be useful for treating patients having cancer. SUMMARY The invention provides compounds of Formula (I) or (II) or a pharmaceutically acceptable salt thereof, as defined in claims 1 to 16. Also provided are compounds of Table 1 or a pharmaceutically acceptable salt thereof, as defined in claim 17. Also provided is a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, as defined in claim 18. Also provided is the pharmaceutical composition, further comprising at least one additional anticancer agent or therapy selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, and ipilimumab, and at least one pharmaceutically acceptable excipient, as defined in claim 19. Also provided is the compound or pharmaceutically acceptable salt thereof, for use in treating cancer, as defined in claim 20. DETAILED DESCRIPTION Definitions As used in the present disclosure, the following words and phrases are generally intended to have the meanings as set forth below unless expressly indicated otherwise or the context in which they are used indicates otherwise. The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments. As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise. A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(O)NH2 is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named. A squiggly line on a chemical group as shown belo